key: cord-1011262-yz5cv4tp authors: Cocoros, Noelle M.; Fuller, Candace C.; Adimadhyam, Sruthi; Ball, Robert; Brown, Jeffrey S.; Dal Pan, Gerald J.; Kluberg, Sheryl A.; Lo Re, Vincent; Maro, Judith C.; Nguyen, Michael; Orr, Robert; Paraoan, Dianne; Perlin, Jonathan; Poland, Russell E.; Driscoll, Meighan Rogers; Sands, Kenneth; Toh, Sengwee; Yih, W. Katherine; Platt, Richard title: A COVID‐19‐ready public health surveillance system: The Food and Drug Administration's Sentinel System date: 2021-04-18 journal: Pharmacoepidemiol Drug Saf DOI: 10.1002/pds.5240 sha: 1357e73c5fcdf812401d6a24d9dbf85a5505e6d0 doc_id: 1011262 cord_uid: yz5cv4tp The US Food and Drug Administration's Sentinel System was established in 2009 to use routinely collected electronic health data for improving the national capability to assess post‐market medical product safety. Over more than a decade, Sentinel has become an integral part of FDA's surveillance capabilities and has been used to conduct analyses that have contributed to regulatory decisions. FDA's role in the COVID‐19 pandemic response has necessitated an expansion and enhancement of Sentinel. Here we describe how the Sentinel System has supported FDA's response to the COVID‐19 pandemic. We highlight new capabilities developed, key data generated to date, and lessons learned, particularly with respect to working with inpatient electronic health record data. Early in the pandemic, Sentinel developed a multi‐pronged approach to support FDA's anticipated data and analytic needs. It incorporated new data sources, created a rapidly refreshed database, developed protocols to assess the natural history of COVID‐19, validated a diagnosis‐code based algorithm for identifying patients with COVID‐19 in administrative claims data, and coordinated with other national and international initiatives. Sentinel is poised to answer important questions about the natural history of COVID‐19 and is positioned to use this information to study the use, safety, and potentially the effectiveness of medical products used for COVID‐19 prevention and treatment. and efficient surveillance to characterize large and diverse patient populations and monitor medical product use, safety, and effectiveness. The US Food and Drug Administration (FDA)'s roles in pandemic response necessitated an expansion and enhancement of one of the Agency's core active surveillance capabilities, the Sentinel System. Sentinel has implemented an array of pandemic response activities, building on more than a decade of partnerships and growing analytic capacity. Here we describe how the Sentinel System has supported FDA's response to the COVID-19 pandemic, demonstrating its ability to generate important, timely data and descriptive epidemiology for ongoing decision-making and to inform and enable future treatment studies. The Sentinel System was established in 2009 to use electronic health data for improving the national capability to assess post-market medical product safety, with an intent to also serve a broader set of needs for FDA and others. [1] [2] [3] [4] Sentinel's data are based primarily on administrative claims and electronic health records (EHRs). The core Data Partner organizations include national and regional health plans partners, integrated delivery systems, and Medicare-fee-for service data. Sentinel operates as a privacy-preserving distributed data network, 5, 6 with each organization maintaining possession and operational control over its data. To allow efficient and consistent implementation of a study across the System's distinct sources, each core Several key Sentinel initiatives completed before the pandemic laid the groundwork for COVID-19 activities. In 2018, the FDA began leveraging advances in real-world evidence generation by building capacity to monitor treatments and outcomes during a public health crisis without burdening the medical system. 11 As part of that initiative, we enhanced Sentinel to collect and analyze data on treatments and outcomes relevant to a public health emergency. 12 One aspect of this medical countermeasure related work focused on HCA Healthcare's inpatient EHR data from 140 affiliated hospitals in 18 states. Designed to allow near real-time monitoring of influenza-a proxy for a public health emergency-the system was reconfigured to assess COVID-19 in April 2020. As described below, Sentinel can actively monitor the characteristics, treatments, and outcomes of patients with COVID-19 in these data. Other prior work in influenza, including use of near real-time claims data and novel methods for active safety surveillance, contributed to Sentinel's ability to rapidly respond to COVID-19. [13] [14] [15] Key Points • The US FDA enhanced the Sentinel System to assess the use and performance of drugs and biologics in preventing and treating COVID-19. • A natural history master protocol to guide COVID-19 studies that rely on real-world data was developed, as was a protocol to study arterial and venous thrombotic events among patients with COVID-19. • Monitoring systems have been established that are sustainable and flexible, including routine reports examining inpatient characteristics, treatments, and outcomes of COVID-19. • Many of these activities are expected to be useful for other surveillance and epidemiology initiatives. • Sentinel's diverse network of partners, varied sources of electronic healthcare data, and deep experience of maintaining such as system has enabled Sentinel to support FDA's public health emergency response. Early in the pandemic Sentinel developed a multi-pronged approach to expand its capabilities to support FDA's anticipated data and analytic needs. FDA's interests in using Sentinel data include the assessment of drug and biologic use in the prevention and treatment of COVID-19 and preparation for assessing the performance of such products. We enhanced the data model, incorporated new data sources, and created a rapidly refreshed database. Sentinel also (a) developed new protocols, including a "Master Protocol" to assess the natural history of COVID-19 as the pandemic continued, providing a foundation for evaluating new therapies, (b) undertook a study to validate COVID-19 diagnosis in claims data, and (c) coordinated with other national and international initiatives. As part of FDA-Catalyst, 16 which supplements Sentinel with access to patient reported data, FDA modified its MyStudies smartphone app to enable virtual participant consent in trials. Taken together, these projects support the Agency's ability to study COVID-19 disease and its treatments. We added SARS-CoV-2 laboratory test results to the Common Data Model. To provide timely analyses, we worked with several large national health plans and regional integrated delivery systems to increase the frequency and reduce the latency for updates of the claims portions of the distributed data (typically 4-6 months from time of care), refreshing core elements of the distributed database and COVID-19 diagnostic test results every approximately 4-6 weeks. The most specific way to define a COVID-19 cohort for analysis is to include only patients with a positive diagnostic test for SARS-CoV-2. Currently, the Centers for Disease Control and Prevention considers a positive nucleic acid amplification detection test as confirmatory. 17 However, most claims data sources, including Medicare, have incomplete laboratory test results, yet comprehensively capture other medical care. Therefore, it is essential to develop diagnosis code-based algorithms which accurately identify COVID-19 to augment laboratoryconfirmed cases to identify COVID-19 cohorts. We conducted a validation study in six health plans of multiple algorithms based on International Classification of Diseases, Tenth Revision, Clinical Modification diagnosis codes for identifying individuals hospitalized with COVID- 19 . 18 We found that the COVID-19-specific code U07.1, available since April 2020, had a positive predictive value of 81.2% (95% CI, 80.1%-82.2%) and sensitivity of 94.9% (95% CI, 94.2%-95.5%). The high performance of the algorithm provides confidence for using diagnosis codes to identify hospitalized COVID-19 individuals in the absence of complete laboratory data for many epidemiologic purposes. Because COVID-19 is a novel disease, its natural history must be documented to provide essential reference data for new treatments. We developed a natural history Master Protocol to serve as a guide for an array of COVID-19 studies that rely on claims, EHR, or linked claims and EHR data. This work enables studies funded by FDA and others to share common approaches and definitions where appropriate. Data obtained from this protocol will allow researchers to address the feasibility of planned future studies, and to identify limitations and potential biases. Numerous reports have described thrombotic events among patients hospitalized with COVID-19. [20] [21] [22] To guide the study of these events, we developed a protocol to estimate the incidence of arterial and venous thrombotic events among patients with COVID-19. It compares the risk of these events among those with COVID-19 to patients with seasonal influenza using propensity score-based adjustment. This will allow us to elucidate whether COVID-19 infection increases the risk of thrombosis compared to another common respiratory virus with pandemic potential. The protocol also addresses the identification of risk factors for arterial and venous thrombotic events, particularly patient characteristics that promote stasis of circulation (e.g., obesity, atrial fibrillation), endothelial injury (e.g., diabetes, hypertension), and hypercoagulability (e.g., cancer, history of prior venous thromboembolism). Within Sentinel, the protocol is being implemented with data from integrated delivery systems and national claims partners, building on the strengths inherent to each source. This protocol has been posted on the Sentinel website 23 and was disseminated through the COVID-19-Evidence Accelerator sponsored by the Reagan-Udall Foundation, 24 guiding work by others. To monitor patterns of care and clinical outcomes, we leveraged Sentinel's pandemic preparation activities to develop a surveillance report of COVID-19 census and clinical characteristics in HCA Healthcare. We identified hospitalizations with a COVID-19-specific diagnosis code, as well as those with a positive SARS-CoV-2 diagnostic test mechanically ventilated or on supplemental oxygen, and 11% died in hospital. Figure 1 shows the proportion of those diagnosed with COVID-19 who received selected medications. There was an increase in remdesivir following FDA emergency use authorization 26 and an increase in dexamethasone following publication of the RECOVERY trial. 27 Several monoclonal antibodies have been authorized for emergency use against COVID-19 by FDA. Sentinel plans on using HCA and the rapidly refreshed database to assess their use and safety by monitoring for infusion-related reactions and other potential safety issues, should they arise. In order to study the impact of COVID-19 on pregnancy, as large a sample of pregnant women with COVID-19 as possible is needed. Toward that end, the FDA has partnered with the European Medicines Agency (EMA). The EMA is initiating a project called CONSIGN ("COVID-19 infectiOn aNd medicineS In preGNancy") that will study the natural history of COVID-19 disease in pregnant women across eight European countries. 28 Sentinel has joined this international collaboration, implementing a study aligned with CONSIGN. We will use Sentinel's validated analytic tools to estimate the prevalence of select medicines in pregnant women with and without COVID-19, and in nonpregnant women with COVID-19. We will also describe disease severity and clinical outcomes of pregnant women with COVID-19, according to treatments, age, and trimester during pregnancy, compared to nonpregnant women with COVID-19. There is potential for shortages of products used to treat COVID-19 patients, as well as other drugs, due to supply chain interruptions. Sentinel developed new capabilities early in the pandemic to assess regional and temporal patterns of inpatient use of 120 critical medications. With a need for near real-time monitoring and geographic diversity we leveraged partnerships with several database systems including HCA Healthcare and multiple EHR data aggregators including TriNetX, Veradigm, and IBM Explorys. Each partner has access to near real-time EHR data that includes prescriptions and medication administrations. Inpatient medication utilization is reported along with measures of COVID-19 burden, defined as rates of hospitalizations by state and week. We routinized reporting for these metrics, with historic data for comparison. Similar to Figure 1 , we have observed variation and changes in medication utilization that coincide with medical knowledge advances or policy events. We have also observed regional variation in the use of some drugs. settings, to support NHLBI's ACTIV trials. 37 The EMA will conduct a study aligned with the one described above examining thrombotic events among patients with COVID-19 and a meta-analysis may ultimately be conducted with the EMA-and FDA-sponsored results. 36 The pandemic has underscored the importance of timely nation-scale clinical information. While EHRs are now routinely used, the ideal data-EHR information from every provider and facility, linkable with a unique patient identifier to create a complete and clinically rich lon- identified substantially more patients with indicators of severe disease. In initial analyses we found that 75% of patients diagnosed with COVID-19 had evidence of oxygen use or mechanical ventilation, compared to 26% when procedure codes were used. The nation requires public health surveillance systems capable of monitoring the occurrence of serious illnesses as well as assessing the use, safety, and effectiveness of treatments. FDA's long-term investment in Sentinel has made possible the program's ability to respond to the COVID-19 pandemic. We have initiated a wide range of projects using data from many sources. The products of these initiatives are expected to be useful beyond FDA's needs. Numerous monitoring systems have been established that are sustainable and flexible. Sentinel is poised to answer important questions about the natural history of COVID-19 and is positioned to use this information to study the use, safety, and potentially the effectiveness of medical products used for prevention and treatment. Routinely collected electronic health information, coupled with commitment to a network of diverse partners, can fulfill the long-held promise of supporting essential public health needs during an emergency. 39 This ability depends on FDA's sustained investment in understanding dynamic local variations in documentation, coding, and storage of data, the appropriate use of different data for different purposes, and expertise in the scientific and practical aspects of maintaining a system such as Sentinel. Developing the Sentinel System-a national resource for evidence development The US Food and Drug Administration's sentinel initiative: expanding the horizons of medical product safety The FDA's sentinel initiative-a comprehensive approach to medical product surveillance The FDA sentinel initiative-an evolving National Resource Design of a National Distributed Health Data Network Distributed health data networks: a practical and preferred approach to multiinstitutional evaluations of comparative effectiveness, safety, and quality of care Design considerations, architecture, and use of the Mini-Sentinel distributed data system: Use of the mini-sentinel distributed database Completed ARIA Assessments & Impact j Sentinel Initiative Publications & Presentations j Sentinel Initiative Electronic Code of Federal Regulations (eCFR) [Internet]. Electronic Code of Federal Regulations (eCFR) Monitoring and assessment of medical countermeasures as part of a public health emergency response Assessing Sentinel System Capability to Collect and Analyze Medical Countermeasure Data for the FDA Office of Counterterrorism and Emerging Threats (OCET) j Sentinel Initiative Prospective influenza vaccine safety surveillance using fresh data in the Sentinel System Assessment of quadrivalent human papillomavirus vaccine safety using the self-controlled treetemporal scan statistic signal-detection method in the sentinel system Outpatient influenza antivirals in a distributed data network for influenza surveillance FDA-Catalyst Projects COVID-19) j 2020 Interim Case Definition ICPE Presentation: Validation of Claims-based Algorithms to Identify Hospitalized COVID-19 Events within the FDA Sentinel System Master Protocol Development: COVID-19 Natural History Sentinel Initiative. 2020 Incidence of thrombotic complications in critically ill ICU patients with COVID-19 Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients Descriptive Assessment of the Natural History of Coagulopathy in COVID-19 Evidence Accelerator Home j Evidence Accelerator The US influenza hospitalization surveillance network. Emerg Infect Dis COVID-19) Update: FDA Issues Emergency Use Authorization for Potential COVID-19 Treatment Dexamethasone in hospitalized patients with Covid-19-preliminary report COVID-19: EMA sets up infrastructure for real-world monitoring of treatments and vaccines The FDA MyStudies app: a reusable platform for distributed clinical trials and real-world evidence studies Foundation COVID-19 Evidence Accelerator. Descriptive assessment of coagulopathy among COVID-19 patients: feasibility data review Foundation COVID-19 Evidence Accelerator. Assessing data source characteristics in multi-site analyses Foundation COVID-19 Evidence Accelerator. Defining COVID-19 cohorts in real-world data Foundation COVID-19 Evidence Accelerator. Risk of thromboembolic events with COVID-19: a sentinel system investigation -focus on endpoints Foundation COVID-19 Evidence Accelerator. Risk of thromboembolic events with COVID-19: a sentinel system investigation -update on methods Foundation COVID-19 Evidence Accelerator. Coagulopathy assessment in patients with COVID-19: a TriNetX analysis COVID-19 Real-World Evidence and Observational studies j International Coalition of Medicines Regulatory Authorities (ICMRA) National Institutes of Health (NIH) Validation of intensive care and mechanical ventilation codes in Medicare data Infectious disease surveillance in the big data era: towards faster and locally relevant systems Changes in hospitalized coronavirus disease 2019 (COVID-19) patient characteristics and resource use in a system of community hospitals in the United States Patient characteristics and admitting vital signs associated with coronavirus disease 2019 (COVID-19)-related mortality among patients admitted with noncritical illness A COVID-19-ready public health surveillance system: The Food and Drug Administration's Sentinel System The authors declare no conflict of interest.